Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Art games Stories

2014-02-25 12:28:26

VANCOUVER, Feb. 25, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced that its United States trading symbol ICOTF has received approval from The Depository Trust Company (the "DTC"), thus providing the Company with DTC eligibility. DTC eligibility allows for iCo Therapeutics shares to be easily and economically transferred between brokerage accounts electronically. The DTC is the largest securities depository in the...

2013-12-12 12:27:07

VANCOUVER, Dec. 12, 2013 /PRNewswire/ - iCo Therapeutics (TSX-V: ICO), today announced that on November 26, 2013, U.S. patent 8,592,382 was issued for the Oral Amphotericin B platform (Oral AmpB) providing protection around oral delivery of the drug. With the recent receipt of ethics approval, the Oral AmpB technology is also moving into in vitro testing with study partners in Montreal, and will examine the role of this formulation in targeting latent HIV reservoirs which remain...

2013-09-05 16:26:17

VANCOUVER, Sept. 5, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO), today announced that on September 5, 2013 the Company granted a total of 40,000 stock options to a director of the Company.  The stock options are exercisable into common shares of the Company at an exercise price of $0.45 for a period of five years and are subject to vesting requirements.  The Company's common shares closed at $0.45 on the TSX Venture Exchange on September 5,...

2013-09-04 08:30:46

VANCOUVER, Sept. 4, 2013 /PRNewswire/ - iCo Therapeutics Inc. (TSX-V: ICO), today announced it will be presenting at the Rodman & Renshaw 2013 Annual Global Investment Conference. The conference, sponsored by H.C. Wainwright & Co., LLC, is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City. Management will deliver the Company presentation to conference attendees on Monday, September 9 at 12:30 PM ET. More than 200 public and private...

2013-08-26 16:25:06

VANCOUVER, Aug. 26, 2013 /PRNewswire/ - iCo Therapeutics (TSX-V: ICO), today reported financial results for the quarter ended June 30, 2013. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). "The quarter was strong both operationally and financially," said Andrew Rae, iCo's President & CEO.  "We completed the enrollment of the phase two iDEAL study initiating the countdown to our...

2013-03-28 00:20:41

Journey Takes Home Six Awards Including Game of the Year; Inaugural Audience Choice Award Goes to Bethesda and Arkane's Dishonored SAN FRANCISCO, March 27, 2013 /PRNewswire/ -- thatgamecompany's emotionally-charged game Journey swept tonight's Game Developers Choice Awards ceremony during GDC 2013 at the Moscone Center in San Francisco, winning six of the evening's eleven main awards, including Best Audio, Best Game Design, Best Visual Arts, Best Downloadable Game, the Innovation...

2012-12-04 12:22:55

ATHENS, Greece, December 4, 2012 /PRNewswire/ -- Having obsessively researched the wild and wonderful world of indie gaming, Bundle In A Box returns and is proud to present the Eclectic Delights bundle. It's a fine assortment of 9 delightful, truly indie offerings everyone can enjoy for the most reasonable price of "pay-what-you-want" over at http://www.bundle-in-a-box.com. The bundle, a Kyttaro Games (http://www.kyttarogames.com) effort to promote indie developers and...

2012-10-24 11:25:35

CALABASAS, Calif., Oct. 24, 2012 /PRNewswire/ -- The Academy of Interactive Arts & Sciences (AIAS) today unveiled new details and opened registration for the 12(th) Annual D.I.C.E. (Design, Innovate, Communicate, Entertain) Summit and Awards program, at the Hard Rock Hotel and Casino in Las Vegas, February 5 - 8, 2013. The annual event, which draws some of the brightest and most influential interactive entertainment industry leaders, decision makers and visionaries, is evolving...